This site is intended for Healthcare professionals only.

Novartis to buy France’s CellforCure to boost cell, gene therapy


Novartis to buy France’s CellforCure to boost cell, gene therapy

Novartis, which already has an agreement with CellforCure to help make Kymriah, said it aims to add CellforCure’s facilities to a similar factory in Morris Plains, New Jersey, as well as one under construction in Switzerland. Terms of the cash deal were not given.

ZURICH: Novartis is to buy French contract manufacturer CellforCure from biologics company LFB to boost the Swiss drugmaker’s capacity to produce cell and gene therapies such as its $475,000 Kymriah cancer treatment.

Novartis, which already has an agreement with CellforCure to help make Kymriah, said it aims to add CellforCure’s facilities to a similar factory in Morris Plains, New Jersey, as well as one under construction in Switzerland. Terms of the cash deal were not given.

Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Read Also: Novartis to launch epinephrine-rival to EpiPens



Source: With input
0 comment(s) on Novartis to buy France’s CellforCure to boost cell, gene therapy

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted